South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 20 of 53 for "u:pr-inside.com" in South San Francisco, CA

  1. Cytokinetics Announces Publication of Results from Phase II Trial of...Read the original story

    Wednesday Mar 25 | PR-inside.com

    Data from Evidence of Effect Trial Provide Support for Novel Mechanism of Action in Neuromuscular Diseases South San Francisco, CA, March 25, 2015 - Cytokinetics, Incorporated announced the publication of a manuscript relating to its fast skeletal muscle troponin activator tirasemtiv in the journal Neurotherapeutics. This publication summarizes results from a Phase IIa "Evidence of Effect" or hypothesis-generating clinical trial which evaluated tirasemtiv in patients with generalized myasthenia gravis .

    Comment?

  2. New Report Available: MPM Capital, L.P. - Medical Equipment - Investment ProfileRead the original story

    Tuesday Mar 17 | PR-inside.com

    It focuses investments into biotechnology, medical technology, specialty pharma and related companies that provide medical products and services to the healthcare industry. The firm is structured to invest in healthcare innovation globally, irrespective of geography, stage of development and therapeutic area.

    Comment?

  3. Report Published: "diaDexus, Inc. (DDXS) - Financial and Strategic SWOT Analysis Review"Read the original story

    Sunday Mar 15 | PR-inside.com

    The company develops and commercializes in-vitro diagnostic products for the treatment of cardiovascular disease. Its product includes The PLAC Test.

    Comment?

  4. Cytokinetics Announces Completion of Enrollment in COSMIC-HFRead the original story

    Friday Mar 13 | PR-inside.com

    Results Expected Later This Year to Inform Potential Progression of Omecamtiv Mecarbil to Phase III SOUTH SAN FRANCISCO, CA, March 13, 2015 - Cytokinetics, Incorporated announced today that COSMIC-HF has completed enrollment of the approximately 450 patients planned in the expansion phase of the clinical trial. In addition, the company announced that over 200 patients have completed the protocol-specified 20-week duration of dosing in this phase of the trial and reaffirmed that results from COSMIC-HF are expected to be available in the second half of 2015.

    Comment?

  5. Fluidigm Corporation (FLDM) - Medical Equipment - Deals and Alliances Profile - New Study ReleasedRead the original story

    Saturday Mar 7 | PR-inside.com

    The company manufactures and markets microfluidic-based chips and instrumentation for biological research. Its products and systems include biomark HD system, C1 system, EP1 system, access array system, chips and kits, DELTagene assays, SNPtype assays, target-specific primers and software.

    Comment?

  6. Cytokinetics Joins Global Movement to Raise Awareness for Rare DiseasesRead the original story

    Feb 27, 2015 | PR-inside.com

    SOUTH SAN FRANCISCO, CA, February 27, 2015 - Cytokinetics, Incorporated announced today that it is joining forces on February 28 with patients and health care advocates in the United States and globally to raise awareness for Rare Disease Day . Rare Disease Day is dedicated to elevating public understanding of rare diseases and calling attention to the special challenges faced by patients with rare diseases and the support community around them.

    Comment?

  7. Cytokinetics Announces Publication of Preclinical Data Relating to...Read the original story

    Feb 26, 2015 | PR-inside.com

    Manuscript Supports Rationale for Development of CK-2127107 in Diseases Associated with Muscle Weakness and Fatigue South San Francisco, CA, February 26, 2015 - Cytokinetics, Incorporated announced the publication of a manuscript relating to its fast skeletal muscle troponin activator CK-2127107 in The Journal of Pharmacology and Experimental Therapeutics. This publication relates to a preclinical evaluation of CK-2127107 in a rat model of heart failure that demonstrated CK-2127107 was associated with increased exercise performance in this model.

    Comment?

  8. Cytokinetics to Present at Healthcare Conferences in MarchRead the original story

    Feb 24, 2015 | PR-inside.com

    South San Francisco, CA, February 24, 2015 - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences: Cowen and Company 35 Annual Health Care Conference Date: Tuesday, March 3, 2015 Time: 11:20 AM Eastern Time Location: Boston Marriott Copley Place Hotel, Boston, MA 27 Annual ROTH Conference Date: Monday, March 9, 2015 Time: 8:30 AM Pacific Time Location: Ritz-Carlton, Laguna Nigel, Dana Point, CA Interested parties may access the live audio of this presentation by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com.

    Comment?

  9. Portola Pharmaceuticals, Inc. (PTLA) - Pharmaceuticals & Healthcare - ...Read the original story

    Feb 20, 2015 | PR-inside.com

    It undertakes the discovery and development of innovative therapeutics for the treatment of cardiovascular, inflammation, and oncology indications. The company's product portfolio includes Betrixaban, Andexanet Alfa , PRT2607, and PRT2070.

    Comment?

  10. Market Report, "Nodality, Inc. - Pharmaceuticals & Healthcare - Deals ...Read the original story

    Feb 19, 2015 | PR-inside.com

    Nodality, Inc. is a biotechnology company. The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients.

    Comment?

  11. Cytokinetics, Incorporated Reports Fourth Quarter 2014 Financial ResultsRead the original story

    Feb 12, 2015 | PR-inside.com

    Ongoing Regulatory Interactions in US and Europe Inform Progression of Tirasemtiv to Phase III COSMIC-HF Nears Completion of Enrollment with Results Expected Later This Year Company Exceeded Financial Guidance in 2014 and Provides Milestones and Financial Guidance for 2015 SOUTH SAN FRANCISCO, CA, February 12, 2015 - Cytokinetics, Incorporated reported total research and development revenues for the fourth quarter of 2014 were $21.8 million, compared to $24.3 million during the same period in 2013. The net income for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share.

    Comment?

  12. Recent Study: Poniard Pharmaceuticals, Inc. (PARD) - Pharmaceuticals...Read the original story

    Feb 12, 2015 | PR-inside.com

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.

    Comment?

  13. Now Available: Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Feb 11, 2015 | PR-inside.com

    The company develops therapeutics for the treatment of central nervous system disorders. Its products include probuphine used for the treatment of opioid addiction, iloperidone used for the treatment of schizophrenia and related psychotic disorders.

    Comment?

  14. New Market Report: Talon Therapeutics, Inc. (TLON) - Pharmaceuticals...Read the original story

    Feb 11, 2015 | PR-inside.com

    Talon Therapeutics, Inc. is a biopharmaceutical company. It researches, develops and commercializes products for cancer.

    Comment?

  15. Fluidigm Corporation - Pharmaceuticals & Healthcare - Deals and...Read the original story

    Feb 2, 2015 | PR-inside.com

    The company manufactures and markets microfluidic-based chips and instrumentation for biological research. Its products and systems include biomark HD system, C1 system, EP1 system, access array system, chips and kits, DELTagene assays, SNPtype assays, target-specific primers and software.

    Comment?

  16. Cytokinetics to Announce Fourth Quarter Results on February 12, 2015Read the original story

    Jan 29, 2015 | PR-inside.com

    South San Francisco, CA., January 29, 2015, - Cytokinetics, Incorporated announced today that it is scheduled to report fourth quarter results on Thursday, February 12, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

    Comment?

  17. Market Report, "Poniard Pharmaceuticals, Inc. (PARD) - Financial and...Read the original story

    Jan 27, 2015 | PR-inside.com

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.

    Comment?

  18. "Theravance, Inc. (THRX) - Financial and Strategic SWOT Analysis Review" PublishedRead the original story

    Jan 17, 2015 | PR-inside.com

    Theravance, Inc. is a biopharmaceutical company. The company discovers, develops and commercializes small molecule medicines.

    Comment?

  19. New Report Available: Sunesis Pharmaceuticals, Inc. - Strategy and SWOT ReportRead the original story

    Jan 16, 2015 | PR-inside.com

    The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

    Comment?

  20. Rigel Pharmaceuticals, Inc. - Strategy and SWOT Report - New Study ReleasedRead the original story

    Jan 16, 2015 | PR-inside.com

    Rigel Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.